S&P 500   4,538.43
DOW   34,580.08
QQQ   383.13
S&P 500   4,538.43
DOW   34,580.08
QQQ   383.13
S&P 500   4,538.43
DOW   34,580.08
QQQ   383.13
S&P 500   4,538.43
DOW   34,580.08
QQQ   383.13
NASDAQ:ALRN

Aileron Therapeutics Stock Forecast, Price & News

$0.58
-0.01 (-1.70%)
(As of 12/3/2021 12:00 AM ET)
Add
Compare
Today's Range
$0.57
$0.60
50-Day Range
$0.57
$1.07
52-Week Range
$0.55
$2.33
Volume
364,002 shs
Average Volume
522,298 shs
Market Capitalization
$52.52 million
P/E Ratio
N/A
Dividend Yield
N/A
Beta
2.62
30 days | 90 days | 365 days | Advanced Chart
Receive ALRN News and Ratings via Email

Sign-up to receive the latest news and ratings for Aileron Therapeutics and its competitors with MarketBeat's FREE daily newsletter.


Aileron Therapeutics logo

About Aileron Therapeutics

Aileron Therapeutics, Inc. operates as a clinical stage biopharmaceutical company. The firm engages in the development and commercialization of novel class of therapeutics for the treatment of cancer and other diseases. It focuses on its lead products candidate, ALRN-6924 which is a cell-permeating peptide that disrupts the interaction of p53 suppressors MDM2 and MDMX with tumor suppressor p53 to reactivate tumor suppression in non-mutant, or wild-type, p53 cancers. The company was founded by Gregory L. Verdine, Rosana Kapeller, Huw M. Nash, Joseph A. Yanchik III and Loren David Walensky on August 6, 2001 and is headquartered in Watertown, MA.

Headlines

See More Headlines

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:ALRN
Fax
N/A
Employees
8
Year Founded
N/A

Sales & Book Value

Annual Sales
N/A
Book Value
$0.55 per share

Profitability

Net Income
$-21.16 million
Pretax Margin
N/A

Debt

Price-To-Earnings

Miscellaneous

Free Float
88,038,000
Market Cap
$52.52 million
Optionable
Not Optionable

Company Calendar

Last Earnings
11/12/2021
Today
12/05/2021
Fiscal Year End
12/31/2021
Next Earnings (Estimated)
3/23/2022

MarketRank

Overall MarketRank

1.61 out of 5 stars

Medical Sector

1027th out of 1,388 stocks

Pharmaceutical Preparations Industry

490th out of 668 stocks

Analyst Opinion: 3.5Community Rank: 4.5Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -












Aileron Therapeutics (NASDAQ:ALRN) Frequently Asked Questions

Is Aileron Therapeutics a buy right now?

2 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Aileron Therapeutics in the last twelve months. There are currently 2 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" Aileron Therapeutics stock.
View analyst ratings for Aileron Therapeutics
or view top-rated stocks.

How has Aileron Therapeutics' stock price been impacted by Coronavirus (COVID-19)?

Aileron Therapeutics' stock was trading at $0.4031 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization (WHO). Since then, ALRN stock has increased by 43.9% and is now trading at $0.5799.
View which stocks have been most impacted by COVID-19
.

Are investors shorting Aileron Therapeutics?

Aileron Therapeutics saw a decline in short interest in the month of November. As of November 15th, there was short interest totaling 890,400 shares, a decline of 26.4% from the October 31st total of 1,210,000 shares. Based on an average daily trading volume, of 587,200 shares, the short-interest ratio is currently 1.5 days. Approximately 1.4% of the shares of the stock are sold short.
View Aileron Therapeutics' Short Interest
.

When is Aileron Therapeutics' next earnings date?

Aileron Therapeutics is scheduled to release its next quarterly earnings announcement on Wednesday, March 23rd 2022.
View our earnings forecast for Aileron Therapeutics
.

How were Aileron Therapeutics' earnings last quarter?

Aileron Therapeutics, Inc. (NASDAQ:ALRN) released its quarterly earnings data on Friday, November, 12th. The company reported ($0.07) earnings per share for the quarter, hitting analysts' consensus estimates of ($0.07).
View Aileron Therapeutics' earnings history
.

What price target have analysts set for ALRN?

2 equities research analysts have issued 1-year price objectives for Aileron Therapeutics' stock. Their forecasts range from $2.00 to $5.00. On average, they anticipate Aileron Therapeutics' share price to reach $3.50 in the next year. This suggests a possible upside of 503.6% from the stock's current price.
View analysts' price targets for Aileron Therapeutics
or view top-rated stocks among Wall Street analysts.

Who are Aileron Therapeutics' key executives?

Aileron Therapeutics' management team includes the following people:
  • Manuel C. Alves Aivado, President, Chief Executive Officer & Director
  • Richard J. Wanstall, Chief Financial Officer & Treasurer
  • Vojislav Vukovic, Chief Medical Officer & Senior Vice President
  • Dora Ferrari, VP-Clinical Development & Program Management
  • David Allen Annis, Senior Vice President-Research

What other stocks do shareholders of Aileron Therapeutics own?

When did Aileron Therapeutics IPO?

(ALRN) raised $61 million in an initial public offering (IPO) on Thursday, June 29th 2017. The company issued 3,800,000 shares at $15.00-$17.00 per share. BofA Merrill Lynch and Jefferies served as the underwriters for the IPO and William Blair and Canaccord Genuity were co-managers.

What is Aileron Therapeutics' stock symbol?

Aileron Therapeutics trades on the NASDAQ under the ticker symbol "ALRN."

Who are Aileron Therapeutics' major shareholders?

Aileron Therapeutics' stock is owned by many different institutional and retail investors. Top institutional investors include Geode Capital Management LLC (0.91%), Renaissance Technologies LLC (0.81%), Game Plan Financial Advisors LLC (0.14%), Keebeck Wealth Management LLC (0.08%), Morgan Jess S & Co. Inc. (0.08%) and JFS Wealth Advisors LLC (0.04%). Company insiders that own Aileron Therapeutics stock include Muneer A Satter, Reinhard J Ambros and Rickenbach Josef H Von.
View institutional ownership trends for Aileron Therapeutics
.

Which major investors are selling Aileron Therapeutics stock?

ALRN stock was sold by a variety of institutional investors in the last quarter, including Renaissance Technologies LLC, and Keebeck Wealth Management LLC.
View insider buying and selling activity for Aileron Therapeutics
or view top insider-selling stocks.

Which major investors are buying Aileron Therapeutics stock?

ALRN stock was acquired by a variety of institutional investors in the last quarter, including Morgan Jess S & Co. Inc., Geode Capital Management LLC, JFS Wealth Advisors LLC, Game Plan Financial Advisors LLC, and Barclays PLC. Company insiders that have bought Aileron Therapeutics stock in the last two years include Muneer A Satter, Reinhard J Ambros, and Rickenbach Josef H Von.
View insider buying and selling activity for Aileron Therapeutics
or or view top insider-buying stocks.

How do I buy shares of Aileron Therapeutics?

Shares of ALRN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Aileron Therapeutics' stock price today?

One share of ALRN stock can currently be purchased for approximately $0.58.

How much money does Aileron Therapeutics make?

Aileron Therapeutics has a market capitalization of $52.52 million. The company earns $-21.16 million in net income (profit) each year or ($0.33) on an earnings per share basis.

How many employees does Aileron Therapeutics have?

Aileron Therapeutics employs 8 workers across the globe.

What is Aileron Therapeutics' official website?

The official website for Aileron Therapeutics is www.aileronrx.com.

Where are Aileron Therapeutics' headquarters?

Aileron Therapeutics is headquartered at 490 Arsenal Way, Watertown MA, 02472.

How can I contact Aileron Therapeutics?

Aileron Therapeutics' mailing address is 490 Arsenal Way, Watertown MA, 02472. The company can be reached via phone at (617) 995-0900 or via email at [email protected].


This page was last updated on 12/5/2021 by MarketBeat.com Staff

Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.